April 3rd 2024
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
The Monoaminergic System and Its Putative Role in Alzheimer Disease
August 14th 2014The SSRIs, although principally targeting serotonin transporter, are complex drugs that might work on other neurotransmitter and receptor systems. It is likely worthwhile to look at the effects of other monoamine and neuropeptide systems on the enzymatic machinery cleaving the amyloid precursor protein.
Read More
Deep Brain Stimulation for Depression and Alzheimer Disease: An Emerging Therapy
November 11th 2013Demographic shifts and rising life expectancies will lead to an epidemic of chronic neuropsychiatric disease, and societal and public health costs will be enormous. Deep brain stimulation--a procedure that interfaces directly with the neural elements that drive pathological behavior--could be useful.
Read More
No Mortality Increase With Antipsychotics in Prospective Study
June 17th 2013Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.
Read More
SuperAgers: Insights Into the Brains of 80+-Year-Old Memory Superstars
June 6th 2013Despite the prevalent perception that cognitive decline in the aged population is inevitable, researchers with Northwestern University's SuperAging Project are finding that "excellent memory capacity in late life is a biological possibility."
Read More
Deep Brain Stimulation: Evidence Based Science or Wishful Thinking?
May 28th 2013Because of new imaging techniques and advances in our understanding of neurophysiology, neurological and psychiatric disorders are increasingly being recognized as disorders of circuit functions in the brain. Using techniques such as DBS, neurosurgeons are able to pinpoint malfunctioning circuits and to recalibrate them.
Read More
Deep Brain Stimulation: New Promise in Alzheimer Disease and Depression?
December 13th 2012The evolution of deep brain stimulation for various neuropsychiatric disorders results from advances in structural and functional brain imaging, increased understanding of neurocircuitry of the brain, and improvements in neurosurgical techniques and equipment.
Read More
Brain Aging and Dementia: Practical Tips From Clinical Research
June 29th 2012Age is a major risk factor for the development of Alzheimer disease and other dementias. New technologies in brain imaging represent major advances in our ability to diagnose age-related cognitive and behavioral disorders.
Read More
Mild Cognitive Impairment-An Added Value to Patient and Physician
February 29th 2012While there are currently no treatments for AD, it is important to examine what we are treating. By the time AD is diagnosed by clinical symptoms, 8 to possibly 15 years of pathological damage has already occurred.
Read More
Video: Delaying Symptom Deterioration in Alzheimer Dementia
December 17th 2011Anton Porsteinsson, MD, discusses some specifics for fine-tuning the care of patients with Alzheimer disease. Here: optimizing physical health and mental stimulation and promoting a brain-healthy diet and aerobic exercise.
Read More
Video: Determinants of Alzheimer Disease -- Is Our Destiny Genetic?
December 17th 2011In this video, Anton Porsteinsson, MD, discusses some of the causative factors of Alzheimer disease: genetics, environment, personality. He goes on to explain that although there are clear determinants for AD, there are preventive actions that can be taken to delay the onset of disability.
Read More
Alzheimer’s Redux: A Preliminary Take on the New Diagnostic Criteria
June 17th 2011If telling patients they have “pre-clinical Alzheimer’s” or “MCI due to Alzheimer’s Disease”-absent effective treatment-produces more emotional suffering than it relieves, a difficult ethical question arises; namely, can such a disclosure be justified under the foundational principle of non-malfeasance?
Read More
Early Alzheimer's Diagnosis and Treatment: Future Hopes, Current Dangers
August 7th 2010The furor surrounding the recently proposed Alzheimer's Guidelines was provoked by their premature attempt to introduce early diagnosis, well before accurate tools are available. The same laudable, but currently clearly unrealistic ambition has propelled two of the worst suggestions for new diagnoses in DSM-5: Psychosis Risk and Mild Neurocognitive.
Read More
Alzheimer's Tests: A Research Tool Not Ready For Clinical Use
August 5th 2010In July, panels sponsored jointly by the National Institute of Aging and the Alzheimer's Association presented controversial proposed guidelines for diagnosing Alzheimer's at three different stages of its progression.
Read More
New Guidelines For Diagnosing Alzheimer's: Wishful Thinking... Dangerous Consequences
July 23rd 2010Previously, I have been quite critical of the DSM-5 suggestion to introduce a new diagnosis-- Minor Neurocognitive Disorder--on the grounds that it would create a large false positive problem and would lead to unnecessary worry and cost with no useful intervention.
Read More
Alzheimer’s Disease Without Dis-ease? New Conundrums for Psychiatric Diagnosis and Public Health
July 19th 2010Researchers who have spent their careers studying schizophrenia and mood disorders might be forgiven a bit of “biomarker envy.” At long last, it seems that the neurologists and neuropsychiatrists have developed some fairly sensitive and specific “lab tests” for Alzheimer’s Disease (AD).
Read More
DSM-5: Continuing the Confusion about Aging, Alzheimer’s and Dementia
July 15th 2010Since the early twentieth century, when Alois Alzheimer and Emil Kraepelin constructed it as a unified clinical-pathological entity, Alzheimer’s disease has been both one of the most stable and one of the most problematic neuropsychiatric entities.
Read More
One Step Closer to Getting a Handle on Alzheimer Disease
June 24th 2010The causes of Alzheimer disease and attempts to predict who is at risk for it have been confounding the medical profession ever since Dr Alzheimer first described the disorder in 1906. Finally, a breakthrough in dye and imaging technology may be the key to solving the puzzle.
Read More
Mortality With Antipsychotic Use in Alzheimer Disease
June 11th 2009Mortality in elderly patients with dementia markedly and progressively increases with extended use of antipsychotics, according to the first long-term controlled study of risk in this population. Earlier evidence of this risk was from short-term trials not exceeding 14 weeks.
Read More